Bao Yi-zhong, Wang Dan, Hu Yu-xing, Xu Ai-hong, Sun Mei-zhen, Chen Hong-hong
Institute of Radiation Medicine, Fudan University, Shanghai 200032, China.
Yao Xue Xue Bao. 2011 Nov;46(11):1308-13.
This study is to assess the efficacy of BPCBG on the decorporation of uranium (VI) and protecting human renal proximal tubular epithelial cells (HK-2) against uranium-induced damage. BPCBG at different doses was injected intramuscularly to male SD rats immediately after a single intraperitoneal injection of UO2(CH3COO)2. Twenty-four hours later uranium contents in urine, kidneys and femurs were measured by ICP-MS. After HK-2 cells were exposed to UO2(CH3COO)2 immediately or for 24 h followed by BPCBG treatment at different doses for another 24 or 48 h, the uranium contents in HK-2 cells were measured by ICP-MS, the cell survival was assayed by cell counting kit-8 assay, formation of micronuclei was determined by the cytokinesis-block (CB) micronucleus assay and the production of intracellular reactive oxygen species (ROS) was detected by 2',7'-dichlorofluorescin diacetate (DCFH-DA) oxidation. DTPA-CaNa3 was used as control. It was found that BPCBG at dosages of 60, 120, and 600 micromol kg(-1) resulted in 37%-61% increase in 24 h-urinary uranium excretion, and significantly decreased the amount of uranium retention in kidney and bone to 41%-31% and 86%-42% of uranium-treated group, respectively. After HK-2 cells that had been pre-treated with UO2(CH3COO)2 for 24 h were treated with the chelators for another 24 h, 55%-60% of the intracellular uranium was removed by 10-250 micromol L(-1) of BPCBG. Treatment of uranium-treated HK-2 cells with BPCBG significantly enhanced the cell survival, decreased the formation of micronuclei and inhibited the production of intracellular ROS. Although DTPA-CaNa3 markedly reduced the uranium retention in kidney of rats and HK-2 cells, its efficacy of uranium removal from body was significantly lower than that of BPCBG and it could not protect uranium-induced cell damage. It can be concluded that BPCBG effectively decorporated the uranium from UO2(CH3COO)2-treated rats and HK-2 cells, which was better than DTPA-CaNa3. It could also scavenge the uranium-induced intracellular ROS and protect against the uranium-induced cell damage. BPCBG is worth further investigation.
本研究旨在评估BPCBG对铀(VI)促排及保护人肾近端小管上皮细胞(HK-2)免受铀诱导损伤的效果。单次腹腔注射UO2(CH3COO)2后,立即对雄性SD大鼠进行不同剂量BPCBG的肌肉注射。24小时后,采用电感耦合等离子体质谱法(ICP-MS)测定尿液、肾脏和股骨中的铀含量。HK-2细胞先立即或暴露于UO2(CH3COO)2 24小时,随后用不同剂量的BPCBG再处理24或48小时,之后采用ICP-MS测定HK-2细胞中的铀含量,用细胞计数试剂盒-8法检测细胞存活率,通过胞质分裂阻断(CB)微核试验检测微核形成情况,并用2',7'-二氯荧光素二乙酸酯(DCFH-DA)氧化法检测细胞内活性氧(ROS)的产生。以喷替酸钙钠(DTPA-CaNa3)作为对照。结果发现,剂量为60、120和600 μmol·kg-1的BPCBG使24小时尿铀排泄量增加了37%-61%,并显著降低了肾脏和骨骼中的铀潴留量,分别降至铀处理组的41%-31%和86%-42%。用UO2(CH3COO)先预处理HK-2细胞24小时,再用螯合剂处理24小时后,10-250 μmol·L-1的BPCBG可去除55%-60%的细胞内铀。用BPCBG处理经铀处理的HK-2细胞可显著提高细胞存活率,减少微核形成并抑制细胞内ROS的产生。虽然DTPA-CaNa3显著降低了大鼠肾脏和HK-2细胞中的铀潴留量,但其从体内去除铀的效果明显低于BPCBG,且不能保护细胞免受铀诱导的损伤。可以得出结论,BPCBG能有效促进UO2(CH3COO)2处理的大鼠和HK-2细胞中的铀排出,效果优于DTPA-CaNa3。它还能清除铀诱导产生的细胞内ROS并保护细胞免受铀诱导的损伤。BPCBG值得进一步研究。